Vaccines and therapeutics for immunocompromised patients with COVID-19

Shoham, Shmuel; Batista, Carolina; Amor, Yanis Ben; Ergönül, Önder; Hassanain, Mazen; Hotez, Peter J.; Kang, Gagandeep; Kim, Jerome H.; Lall, Bhavna; Larson, Heidi; Naniche, Denise; Sheahan, Timothy P.; Strub‐Wourgaft, Nathalie; Sow, Samba O.; Wilder‐Smith, Annelies; Yadav, Prashant; Bottazzi, María Elena

doi:10.1016/j.eclinm.2023.101965

Cited by 74 publications

(36 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 2-3% of the general population have reduced immune responses, so they may be at greater risk from SARS-CoV-2 infection 4. Regulatory and governmental bodies, including the US Centers for Disease Control and Prevention and the British Society for Immunology, therefore endorse covid vaccination for immunocompromised people on the grounds that the benefits outweigh the risks (since none of the covid vaccines are live, they’re not thought to pose any more risk to this population than to immunocompetent people5).…”

Section: How Effective Are Sars-cov-2 Vaccines In Immunocompromised P...mentioning

confidence: 99%

What do we know about covid in immunocompromised people?

Lang

2023

BMJ

View full text Add to dashboard Cite

show abstract

Section: How Effective Are Sars-cov-2 Vaccines In Immunocompromised P...mentioning

confidence: 99%

What do we know about covid in immunocompromised people?

Lang

2023

BMJ

View full text Add to dashboard Cite

show abstract

“…Although some may have a reduced response to vaccines, receiving the recommended doses can still provide some level of protection and potentially mitigate severe disease. 10 Given the potential for diminished vaccine response, immunocompromised individuals should be considered for booster doses based on local guidelines and emerging data. In addition to vaccination, immunocompromised individuals should strictly adhere to preventive measures, including wearing masks, maintaining physical distance, practicing good hand hygiene, and avoiding crowded or poorly ventilated settings.…”

Section: Cons Ider Ationsforcovid -19 Patientsinimmun Oco Mpr Omi S E...mentioning

confidence: 99%

“…Vaccination remains a critical preventive measure for this vulnerable population. Although some may have a reduced response to vaccines, receiving the recommended doses can still provide some level of protection and potentially mitigate severe disease 10 . Given the potential for diminished vaccine response, immunocompromised individuals should be considered for booster doses based on local guidelines and emerging data.…”

Section: Considerations For Covid‐19 Patients In Immunocompromised Po...mentioning

confidence: 99%

Unveiling COVID‐19 treatment strategies for immunocompromised individuals: Therapeutic innovations and latest findings

Liu,

Tsai

2024

Int J of Rheum Dis

View full text Add to dashboard Cite

In the past 3 years, targets for therapeutics and strategies for prevention against coronavirus disease 2019 (COVID-19) were identified and developed based on the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of infection. Therapeutics for COVID-19 regarding disease time course, symptoms and interventions, different stages of the SARS-CoV-2 lifecycle, and COVID-19-associated immunomodulatory effects were discussed by Toussi et al. 1 Drug treatment of COVID-19 infection regarding mild-to-moderate COVID-19 disease in the outpatient setting, patients hospitalized with mildto-moderate disease, patients hospitalized with the severe and critical disease were recently reviewed by Lui and Guaraldi. 2 EDITO RIA L

show abstract

“…While the introduction of vaccines in late 2020 undoubtedly represented a turning point in the pandemic, , vaccine adoption and effectiveness are variable. The efficacy of COVID-19 vaccines has been demonstrated to be lower for elderly or immunocompromised individuals, − which is especially problematic because these patients are also among the groups with the highest risk of developing life-threatening COVID-19. − In order to protect this vulnerable population and mitigate the effects of infection among the general population, safe and effective antiviral agents for treatment of disease are needed to complement vaccines, especially as new variants of SARS-CoV-2 continue to appear.…”

Section: Introductionmentioning

confidence: 99%

Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

Shurtleff,

Layton,

Parish

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

As SARS-CoV-2 continues to circulate, antiviral treatments are needed to complement vaccines. The virus's main protease, 3CLPro, is an attractive drug target in part because it recognizes a unique cleavage site, which features a glutamine residue at the P1 position and is not utilized by human proteases. Herein, we report the invention of MK-7845, a novel reversible covalent 3CLPro inhibitor. While most covalent inhibitors of SARS-CoV-2 3CLPro reported to date contain an amide as a Gln mimic at P1, MK-7845 bears a difluorobutyl substituent at this position. SAR analysis and X-ray crystallographic studies indicate that this group interacts with His163, the same residue that forms a hydrogen bond with the amide substituents typically found at P1. In addition to promising in vivo efficacy and an acceptable projected human dose with unboosted pharmacokinetics, MK-7845 exhibits favorable properties for both solubility and absorption that may be attributable to the unusual difluorobutyl substituent.

show abstract

Vaccines and therapeutics for immunocompromised patients with COVID-19

Cited by 74 publications

References 71 publications

What do we know about covid in immunocompromised people?

What do we know about covid in immunocompromised people?

Unveiling COVID‐19 treatment strategies for immunocompromised individuals: Therapeutic innovations and latest findings

Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

Contact Info

Product

Resources

About